NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
Updated: Jun 8, 2022
FUMANBA-1
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)
This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.
Sponsor
Locations:
China
ClinicalTrials.gov Identifier: NCT05066646
Official Title: Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
First Posted: October 4, 2021
Click here to see details on ClinicalTrials.gov
Drug: CT103A
Autologous Anti-BCMA CAR T Cells CT103A (Code C185123)
Autologous Anti-BCMA CAR T Cells CT103A
Autologous Anti-BCMA CAR-T Cells CT103A
Autologous Anti-BCMA CAR-transduced T-cells CT103A
CT 103A
CT-103A
CT103A
EHA 2022 Oral Presentation
EHA 2022 - HYBRID - JUNE 9-17 - VIENNA
UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Locations
China
China, Anhui
China, Henan
China, Hubei
China, Hunan
China, Jiangsu
China, Zhejiang